Association between enterohepatic circulation of bile acid and cholestatic liver disease
-
摘要: 胆汁淤积性肝病的发生与胆汁酸的肠肝循环障碍密切相关,从胆汁酸的代谢、遗传性胆汁淤积症涉及肠肝循环的机制、相关运载体的分子调控,以及现有治疗方案与肠肝循环的关系4个方面进行了阐述,以探讨胆汁淤积性肝病的发病机制,并为新药或新治疗方法的研究提供相关依据。Abstract: The development of cholestatic liver disease is closely associated with the enterohepatic circulation disorder of bile acid. This article elaborates on metabolism of bile acid, enterohepatic circulation-related mechanism of hereditary cholestasis, molecular regulation of related transporters, and association between current therapeutic regimens and enterohepatic circulation, in order to investigate the pathogenesis of cholestatic liver disease and provide a basis for the research on new drugs or therapies.
-
Key words:
- cholic acid /
- enterohepatic circulation /
- cholestasis
-
[1]CAI JS, CHEN JH.The mechanism of enterohepatic circulation in the formation of gallstone disease[J].J Membr Biol, 2014, 247 (11) :1067-1082. [2]FERREBEE CB, DAWSON PA.Metabolic effects of intestinal absorption and enterohepatic cycling of bile acids[J].Acta Pharm Sin B, 2015, 5 (2) :129-134. [3]ANWER MS, STIEGER B.Sodium-dependent bile salt transporters of the SLC10A transporter family:more than solute transporters[J].Pflugers Arch, 2014, 466 (1) :77-89. [4]HENKEL AS, LECUYER B, OLIVARES S, et al.Endoplasmic reticulum stress regulates hepatic bile acid metabolism in mice[J].Cell Mol Gastroenterol Hepatol, 2016, 3 (2) :261-271. [5]KONIG A, GLEBE D.Live cell imaging confocal microscopy analysis of HBV Myr-Pre S1 peptide binding and uptake in NTCP-GFPexpressing Hep G2 cells[J].Methods Mol Biol, 2017, 1540:27-36. [6]SCHADT HS, WOLF A, POGNAN F, et al.Bile acids in drug induced liver injury:key players and surrogate markers[J].Clin Res Hepatol Gastroenterol, 2016, 40 (3) :257-266. [7]YU L, LIU X, LI X, et al.Protective effects of SRT1720 via the HNF1α/FXR signalling pathway and anti-inflammatory mechanisms in mice with estrogen-induced cholestatic liver injury[J].Toxicol Lett, 2016, 264:1-11. [8]XIAO L, PAN G.An important intestinal transporter that regulates the enterohepatic circulation of bile acids and cholesterol homeostasis:the apical sodium-dependent bile acid transporter (SLC10A2/ASBT) [J].Clin Res Hepatol Gastroenterol, 2017.pii:S2210-7401 (17) 30048-7. [9]BAGHDASARYAN A, FUCHS CD, STERREICHER CH, et al.Inhibition of intestinal bile acid absorption improves cholestatic liver and bile duct injury in a mouse model of sclerosing cholangitis[J].J Hepatol, 2016, 64 (3) :674-681. [10]van DER MARK VA, de WAART DR, HO-MOK KS, et al.The lipid flippase heterodimer ATP8B1-CDC50A is essential for surface expression of the apical sodium-dependent bile acid transporter (SLC10A2/ASBT) in intestinal Caco-2 cells[J].Biochim Biophys Acta, 2014, 1842 (12 Pt A) :2378-2386. [11]FARAHMANDFAR MR, CHABOK M, ALADE M, et al.Post cholecystectomy diarrhoea---a systematic review[J].Surg Sci, 2012, 3 (6) :332-338. [12]ZAPF M, DENHAM W, BARRERA E, et al.Patient-centered outcomes after laparoscopic cholecystectomy[J].Surg Endosc, 2013, 27 (12) :4491-4498. [13]WANG C, HUO X, WANG C, et al.OATP and efflux transporter-mediated hepatic uptake and biliary excretion of cilostazol and its metabolites in rats and humans[J].J Pharm Sci, 2017, 106 (9) :2515-2523. [14]SLIJEPCEVIC D, ROSCAM ABBING RLP, KATAFUCHI T, et al.Hepatic uptake of conjugated bile acids is mediated by both NTCPand OATPs and modulated by intestinal sensing of plasma bile acid levels in mice[J].Hepatology, 2017.[Epub ahead of print] [15]VITALE G, PIRILLO M, MANTOVANI V, et al.Bile salt export pump deficiency disease:two novel, late onset, ABCB11 mutations identified by next generation sequencing[J].Ann Hepatol, 2016, 15 (5) :795-800. [16]DAVIT-SPRAUL A, FABRE M, BRANCHEREAU S, et al.ATP8B1 and ABCB11 analysis in 62 children with normal gamma-glutamyl transferase progressive familial intrahepatic cholestasis (PFIC) :phenotypic differences between PFIC1 and PFIC2 and natural history[J].Hepatology, 2010, 51 (5) :1645-1655. [17]TELBISZ, HOMOLYA L.Recent advances in the exploration of the bile salt export pump (BSEP/ABCB11) function[J].Expert Opin Ther Targets, 2016, 20 (4) :501-514. [18]KENNA JG.Current concepts in drug-induced bile salt export pump (BSEP) interference[J].Curr Protoc Toxicol, 2014, 61:23.7.1-15. [19]QIU X, ZHANG Y, LIU T, et al.Disruption of BSEP function in HepaRG cells alters bile acid disposition and is a susceptive factor to drug-induced cholestatic injury[J].Mol Pharm, 2016, 13 (4) :1206-1216. [20]DEVGUN MS, EL-NUJUMI AM, O'DOWD GJ, et al.Novel mutations in the Dubin-Johnson syndrome gene ABCC2/MRP2 and associated biochemical changes[J].Ann Clin Biochem, 2012, 49 (Pt 6) :609-612. [21]UCHIUMI T, TANAMACHI H, KUCHIWAKI K, et al.Mutation and functional analysis of ABCC2/multidrug resistance protein 2 in a Japanese patient with Dubin-Johnson syndrome[J].Hepatol Res, 2013, 43 (5) :569-575. [22]ELFERINK RP, PAULUSMA CC.MRP2 in cholestasis:putting down the anchor[J].J Hepatol, 2015, 63 (6) :1309-1310. [23]KEPPLER D.The roles of MRP2, MRP3, OATP1B1, and OATP1B3 in conjugated hyperbilirubinemia[J].Drug Metab Dispos, 2014, 42 (4) :561-565. [24]van der SCHOOR LW, VERKADE HJ, KUIPERS F, et al.New insights in the biology of ABC transporters ABCC2 and ABCC3:impact on drug disposition[J].Expert Opin Drug Metab Toxicol, 2015, 11 (2) :273-293. [25]MENNONE A, SOROKA CJ, HARRY KM, et al.Role of breast cancer resistance protein in the adaptive response to cholestasis[J].Drug Metab Dispos, 2010, 38 (10) :1673-1678. [26]BAGHDASARYAN A, CHIBA P, TRAUNER M.Clinical application of transcriptional activators of bile salt transporters[J].Mol Aspects Med, 2014, 37:57-76. [27]LANDRIER JF, ELORANTA JJ, VAVRICKA SR, et al.The nuclear receptor for bile acids, FXR, transactivates human organic solute transporter-alpha and-beta genes[J].Am J Physiol Gastrointest Liver Physiol, 2006, 290 (3) :g476-g485. [28]SHARMA A, PODDAR U, AGNIHOTRYS, et al.A novel truncation mutation in ATP8B1 gene in progressive familial intrahepatic cholestasis[J].Indian Pediatr, 2016, 53 (12) :1099-1101. [29]BALASUBRAMANIYAN N, ANANTHANARAYANAN M, SUCHY FJ.Nuclear factor-κB regulates the expression of multiple genes encoding liver transport proteins[J].Am J Physiol Gastrointest Liver Physiol, 2016, 310 (8) :g618-g628. [30]SAMBROTTA M, STRAUTNIEKS S, PAPOULI E, et al.Mutations in TJP2 cause progressive cholestatic liver disease[J].Nat Genet, 2014, 46 (4) :326-328. [31]GONZALES E, TAYLOR SA, DAVIT-SPRAUL A, et al.MYO5Bmutations cause cholestasis with normal serum gamma-glutamyl transferase activity in children without microvillous inclusion disease[J].Hepatology, 2017, 65 (1) :164-173. [32]GIRARD M, LACAILLE F, VERKARRE V, et al.MYO5B and bile salt export pump contribute to cholestatic liver disorder in microvillous inclusion disease[J].Hepatology, 2014, 60 (1) :301-310. [33]QIU YL, GONG JY, FENG JY, et al.Defects in myosin VB are associated with a spectrum of previously undiagnosed lowγ-glutamyltransferase cholestasis[J].Hepatology, 2017, 65 (5) :1655-1669. [34]SCHNEEBERGER K, VOGEL GF, TEUNISSEN H, et al.An inducible mouse model for microvillus inclusion disease reveals a role for myosin Vb in apical and basolateral trafficking[J].Proc Natl Acad Sci U S A, 2015, 112 (40) :12408-12413. [35]MATSUBARA T, LI F, GONZALEZ FJ.FXR signaling in the enterohepatic system[J].Mol Cell Endocrinol, 2013, 368 (1-2) :17-29. [36]GOMEZ-OPSINA N, POTTER CJ, XIAO R, et al.Mutations in the nuclear bile acid receptor FXR cause progresive familial intrahepatic cholestasis[J].Nat Commun, 2016, 7:10713. [37]CHIGNARD N, POUPON R.Targeting farnesoid x receptor in hepatic and biliary inflammatory diseases[J].Gastroenterology, 2009, 137 (2) :734-735. [38]BEUERS U, TRAUNER M, JANSEN P, et al.New paradigms in the treatment of hepatic cholestasis:from UDCA to FXR, PXR and beyond[J].J Hepatol, 2015, 62 (Suppl 1) :s25-s37. [39]FICKERT P, POLLHEIMER MJ, SILBERT D, et al.Differential effects of nor UDCA and UDCA in obstructive cholestasis in mice[J].J Hepatol, 2013, 58 (6) :1201-1208. [40]TRAUNER M, HALILBASIC E, CLAUDEL T, et al.Potential of nor-ursodeoxycholic acid in cholestatic and metabolic disorders[J].Dig Dis, 2015, 33 (3) :433-439. [41]MODICA S, PETRUZZELLI M, BELLAFANTE E, et al.Selective activation of nuclear bile acid receptor FXR in the intestine protects mice against cholestasis[J].Gastroenterology, 2012, 142 (2) :355-365.e1-4. [42]LUO J, KO B, ELLIOTT M, et al.A nontumorigenic variant of FGF19 treats cholestatic liver diseases[J].Sci Transl Med, 2014, 6 (247) :247ra100. [43]WANG KS, TIAO G, BASS LM, et al.Analysis of surgical interruption of the enterohepatic circulation as a treatment for pediatric cholestasis[J].Hepatology, 2017, 65 (5) :1645-1654. [44]GUNAYDIN M, TANDER B, DEMIREL D, et al.Different techniques for biliary diversion in progressive familial intrahepatic cholestasis[J].J Pediatr Surg, 2016, 51 (3) :386-389.引证本文:, ,
本文二维码
计量
- 文章访问数: 3247
- HTML全文浏览量: 60
- PDF下载量: 644
- 被引次数: 0